tradingkey.logo
搜索

AGMB.NB

AGMB
添加自选
10.550USD
-0.490-4.44%
收盘 05/15, 16:00美东报价延迟15分钟
514.17M总市值
亏损市盈率 TTM

AGMB.NB

10.550
-0.490-4.44%

关于 AGMB.NB 公司

Agomab Therapeutics NV is a Belgium-based company. The Company is engaged in research and development services creating therapies for fibrotic and inflammatory diseases. Its activities include discovery research to identify drug candidates that act on pathways involved in fibrosis and tissue repair, such as organ restricted small molecules and growth factor targeting antibodies. The Company also carries out preclinical development, including work on programs, to evaluate drug behavior and readiness before entering human studies. In addition, It conducts clinical development services by sponsoring and managing trials for its pipeline, assessing safety, tolerability, pharmacokinetics, and pharmacodynamics.

AGMB.NB简介

公司代码AGMB
公司名称Agomab Therapeutics NV
上市日期Feb 06, 2026
CEOKnotnerus (Tim)
员工数量- -
证券类型Depository Receipt
年结日Feb 06
公司地址Posthoflei 1/6
城市
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Belgium
邮编2600
电话
网址https://agomab.com/
公司代码AGMB
上市日期Feb 06, 2026
CEOKnotnerus (Tim)

AGMB.NB公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Tim Knotnerus
Mr. Tim Knotnerus
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
10.82K
--
,
,
--
--
Mrs. Ellen Lefever
Mrs. Ellen Lefever
General Counsel
General Counsel
--
--
Dr. Paul van der Horst
Dr. Paul van der Horst
Chief Business Officer
Chief Business Officer
--
--
Dr. Philippe Wiesel
Dr. Philippe Wiesel
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Andrea Saez
Dr. Andrea Saez
Chief Development Officer
Chief Development Officer
--
--
Mr. Pierre Kemula
Mr. Pierre Kemula
Chief Financial Officer
Chief Financial Officer
--
--
Mr. David R. Epstein
Mr. David R. Epstein
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Angelika Jahreis
Ms. Angelika Jahreis
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Colin Bond
Mr. Colin Bond
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Tim Knotnerus
Mr. Tim Knotnerus
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
10.82K
--
,
,
--
--
Mrs. Ellen Lefever
Mrs. Ellen Lefever
General Counsel
General Counsel
--
--
Dr. Paul van der Horst
Dr. Paul van der Horst
Chief Business Officer
Chief Business Officer
--
--
Dr. Philippe Wiesel
Dr. Philippe Wiesel
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Andrea Saez
Dr. Andrea Saez
Chief Development Officer
Chief Development Officer
--
--

收入明细

由于公司未披露,未能获取相关数据
由于公司未披露,未能获取相关数据
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 5月9日 周六
更新时间: 5月9日 周六
持股股东
股东类型
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
9.90%
Pontifax Venture Capital
6.71%
Sanofi SA
5.65%
EQT Life Sciences
2.28%
abrdn Inc.
1.44%
其他
74.02%
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
9.90%
Pontifax Venture Capital
6.71%
Sanofi SA
5.65%
EQT Life Sciences
2.28%
abrdn Inc.
1.44%
其他
74.02%
股东类型
持股股东
占比
Investment Advisor
9.91%
Venture Capital
9.00%
Corporation
5.65%
Investment Advisor/Hedge Fund
1.54%
Hedge Fund
0.41%
Individual Investor
0.02%
其他
73.47%

机构持股

更新时间: 4月1日 周三
更新时间: 4月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2026Q1
10
10.27M
20.86%
+10.21M

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Fidelity Management & Research Company LLC
4.87M
9.9%
+4.87M
--
Feb 27, 2026
EQT Life Sciences
1.13M
2.29%
+1.13M
--
Feb 09, 2026
Knotnerus (Tim)
10.82K
0.02%
+10.82K
--
Feb 06, 2026
查看更多

持股ETF

机构名称
占比
暂无数据

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
除权除息日
类型
比率
暂无数据
公告日期
除权除息日
类型
比率
暂无数据
KeyAI